Compass Therapeutics/$CMPX
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
- Ticker
- $CMPX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 39
- Headquarters
- Boston, United States
- Website
- www.compasstherapeutics.com
CMPX Metrics
BasicAdvanced
$416M
-
-$0.40
0.82
-
Price and volume
Market cap
$416M
Beta
0.82
52-week high
$6.88
52-week low
$1.61
Average daily volume
3M
Financial strength
Current ratio
11.216
Quick ratio
11.153
Long term debt to equity
4.815
Total debt to equity
5.801
Profitability
EBITDA (TTM)
-81.013
Management effectiveness
Return on assets (TTM)
-33.03%
Return on equity (TTM)
-56.66%
Valuation
Price to book
2.51
Price to tangible book (TTM)
2.51
Price to free cash flow (TTM)
-7.452
Free cash flow yield (TTM)
-13.42%
Free cash flow per share (TTM)
-0.31
Growth
Earnings per share change (TTM)
-10.17%
3-year earnings per share growth (CAGR)
3.74%
What the Analysts think about CMPX
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
CMPX Financial Performance
Revenues and expenses
CMPX Earnings Performance
Company profitability
CMPX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.